Answers are grounded in this paper and cite their sources.
A laboratory integrating genomic, epigenomic, transcriptomic and proteomic measurements must decide which specimens can be compared and which targets merit experimental follow-up. KilnBio links assay-specific processing to reproducible comparisons that separate the effects of sample selection, measurement availability and analysis choices. Researchers can run the supplied recipes from the command line or adapt individual stages to a new study. In bladder tumors, restricting the gene expression analysis from 406 patients to the 338 with protein measurements moved the SRC proto-oncogene from 15th to 16th, outside a 15-gene shortlist. Adding protein in those same patients moved SRC to fifth. A separate implementation in limma reproduced the rankings. In K562 leukemia cells, accessibility and histone acetylation together prioritized 22 perturbation-supported enhancer–gene links in 25 slots, compared with 15 using accessibility and 21 using histone acetylation. Each ranking included genomic distance. Requiring sufficient methylation coverage excluded 98 of 1,917 links, including six supported by the screen. Across seven laboratories measuring gene expression, a correction improved agreement between repeated measurements while slightly increasing error in biological contrasts. These comparisons let researchers trace why an integration decision changes the experiments they would pursue and evaluate what the added assay contributes.
No takes yet. Share an insight, caveat, or question.
Dwaraka et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: